177Lu-LNC1010

N/A

Report date: 2025/11/20 16:00:34
NME

Base Information

Drug Name177Lu-LNC1010
Drug Alias Name177Lu-LNC1010
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionSomatostatin receptor 2 modulators
TargetsSomatostatin receptor 2
Therapy Area/IndicationsPancreatic neuroendocrine tumors (pNET)Solid tumoursNeuroendocrine Tumors +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesYantai Lannacheng Biotechnology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesThe First Affiliated Hospital Of Xiamen UniversityYantai Lannacheng Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsPancreatic neuroendocrine tumors (pNET)Neuroendocrine TumorsNeoplasms
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A